ACM
RARE icon

Altium Capital Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Altium Capital Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-70,000
Closed -$2.88M – 94
2024
Q2 		$2.88M Buy
+70,000
New +$2.99M 1.17% 26

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Altium Capital Management's RARE Position: Q3 2024 in Review

Altium Capital Management sold out of Ultragenyx Pharmaceutical (RARE) in Q3 2024, closing a stake of 70,000 shares — an estimated $2.88M sold.

Altium Capital Management first reported a position in RARE in Q2 2024 and held it in 1 quarter. The position peaked at $2.88M in Q2 2024. 300 funds tracked by Wall St. Rank hold RARE as of Q3 2024.

  • Altium Capital Management reported no remaining Ultragenyx Pharmaceutical position as of Q3 2024 after selling out during the quarter.
  • Altium Capital Management sold 70,000 Ultragenyx Pharmaceutical shares in Q3 2024, an estimated $2.88M.
  • Altium Capital Management first reported a position in Ultragenyx Pharmaceutical in Q2 2024 and held it in 1 quarter.
  • Altium Capital Management's Ultragenyx Pharmaceutical position peaked at $2.88M in Q2 2024.
  • 300 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2024.

Based on Altium Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.